Last reviewed · How we verify
Marginal zone lymphoma
Approved treatments
- Imbruvica · AbbVie
Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells. - Revlimid · Bristol-Myers Squibb
Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation. - Imbruvica · Rabin Medical Center
- Brukinsa · Beigene Usa Inc
Brukinsa blocks the BTK protein, which is involved in the activation of B cells. - Lenali · Singapore General Hospital
- Revlimid · M.D. Anderson Cancer Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Marginal zone lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Marginal zone lymphoma treatment landscape brief
- Marginal zone lymphoma treatment updates RSS
Frequently asked questions about Marginal zone lymphoma
What drugs treat Marginal zone lymphoma?
Tracked treatments include Imbruvica, Revlimid, Brukinsa, Lenali.
What is the treatment for Marginal zone lymphoma?
Standard treatment for Marginal zone lymphoma includes Imbruvica, Revlimid, Brukinsa, Lenali. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Marginal zone lymphoma patent cliff · Marginal zone lymphoma CI report
- Treatment: Imbruvica · AbbVie
- Treatment: Revlimid · Bristol-Myers Squibb
- Treatment: Imbruvica · Rabin Medical Center
- Treatment: Brukinsa · Beigene Usa Inc
- Treatment: Lenali · Singapore General Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing